Moleculin Seeks Approval for 21% Equity Plan Expansion and Reverse Split to Regain Nasdaq Compliance
MBRX has more than doubled off its 52-week low of $0.161 on light trading volume (0.3× avg).
Summary
Moleculin's proxy seeks approval for a 21% equity plan expansion and a reverse stock split to regain Nasdaq compliance, with the stock trading at $0.572.
Key Events · Corporate Governance and Compliance · MBRX
-
Equity Plan Expansion to 4.14M Shares
Proposal 3 seeks to increase the 2024 Equity Incentive Plan from 280,010 to 4,141,894 shares — a 3,861,894 share increase representing ~19.9% of the 19,477,380 shares outstanding, with total potential dilution of ~21.3% including outstanding awards.
-
Reverse Split Authorization Sought
Proposal 6 seeks authority for a reverse stock split between 1-for-2 and 1-for-20, with the Board having sole discretion to implement it within one year. The stock traded at $0.572 on the Record Date, below the Nasdaq $1.00 minimum bid requirement.
-
Nasdaq Delisting Risk
The company acknowledges its stock price is below the $1.00 minimum bid requirement and that prior reverse splits (March 2024 and December 2025) did not achieve lasting compliance.
-
Director Resignation Disclosed
Dr. Joy Yan resigned from the Board effective August 10, 2026, not due to any disagreement with the company.
Analysis · MBRX · Life Sciences
Moleculin is asking shareholders to approve a massive expansion of its equity incentive plan — from 280,010 to 4,141,894 shares, representing roughly 19.9% of the current 19.5 million shares outstanding. Combined with existing awards, total potential dilution reaches approximately 21.3%. The company is also seeking authority for a reverse stock split between 1-for-2 and 1-for-20, with the Board having sole discretion to implement it. This comes as the stock trades at $0.572, well below the Nasdaq $1.00 minimum bid requirement, and follows two prior reverse splits (March 2024 and December 2025) that failed to maintain compliance long-term. The equity plan expansion is necessary to continue using equity as compensation while conserving cash, but it represents significant dilution for existing holders. The reverse split authorization is a survival mechanism to avoid delisting, though the company itself acknowledges prior splits have not achieved lasting price stability.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $0.16 to $15.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.